Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
The article discussed the main treatment strategy for patients with platinum-sensitive relapsed the high-grade serous cancer of the ovaries, fallopian tube cancer and primary peritoneal cancer. The commonality of these tumors is caused by the same type of coelomic epithelium of mesodermal origin of...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2016-11-01
|
Series: | Opuholi Ženskoj Reproduktivnoj Sistemy |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/508 |
id |
doaj-b647a6fbdd1744ed92565fed2a4f9c7d |
---|---|
record_format |
Article |
spelling |
doaj-b647a6fbdd1744ed92565fed2a4f9c7d2021-07-29T08:46:51ZrusABV-pressOpuholi Ženskoj Reproduktivnoj Sistemy1994-40981999-86272016-11-01123536110.17650/1994-4098-2016-12-3-53-61510Ovarian cancer: new accents treatment of patients with platinum-sensitive relapsesA. G. Kedrova0A. G. Nikitin1V. V. Kosyy2M. V. Yurova3Federal Research and Clinical Center for Specialized Medical Cares and Medical Technologies, Federal Biomedical Agency of Russia; Institute for Advanced Training, Federal Biomedical Agency of RussiaFederal Research and Clinical Center for Specialized Medical Cares and Medical Technologies, Federal Biomedical Agency of RussiaFederal Research and Clinical Center for Specialized Medical Cares and Medical Technologies, Federal Biomedical Agency of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaThe article discussed the main treatment strategy for patients with platinum-sensitive relapsed the high-grade serous cancer of the ovaries, fallopian tube cancer and primary peritoneal cancer. The commonality of these tumors is caused by the same type of coelomic epithelium of mesodermal origin of the rudiments of Müllerian ducts, as well as similarities in the ways of carcinogenesis: the loss or inactivation of the tumor suppressor TP53, loss of function of proteins BRCA1 and BRCA2 – the controllers of DNA repair and genome integrity. Platinum drugs and PARP inhibitors have priority in treatment – “BRCA-associated” cancers. Maintenance monotherapy with the PARP inhibitor olaparib after platinum prolonged by 7 months progression-free survival. Olaparib will be to benefit patients with a BRCA mutation. Search mutations in the genes BRCA1 and BRCA2 of all high-grade ovarian cancer patients, allow to allocate patients with relapses requiring therapy resumed platinum drugs and continued the PARP inhibitor olaparib. In these cases, Lynparza (olaparib) 400 mg twice daily, as maintenance treatment in patients with platinum-sensitive relapse who had received two or more platinum-based regimens and who had a partial or complete response to their most recent platinum-based regimen and with BRCA-mutation have the greatest likelihood of benefiting from olaparib maintenance treatment.https://ojrs.abvpress.ru/ojrs/article/view/508high grade serous ovarian cancerchemotherapyplatinum-sensitive relapsebrca-associated ovarian cancerovarian cancer geneticshereditary ovarian cancerolaparibparp inhibitors |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
A. G. Kedrova A. G. Nikitin V. V. Kosyy M. V. Yurova |
spellingShingle |
A. G. Kedrova A. G. Nikitin V. V. Kosyy M. V. Yurova Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses Opuholi Ženskoj Reproduktivnoj Sistemy high grade serous ovarian cancer chemotherapy platinum-sensitive relapse brca-associated ovarian cancer ovarian cancer genetics hereditary ovarian cancer olaparib parp inhibitors |
author_facet |
A. G. Kedrova A. G. Nikitin V. V. Kosyy M. V. Yurova |
author_sort |
A. G. Kedrova |
title |
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses |
title_short |
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses |
title_full |
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses |
title_fullStr |
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses |
title_full_unstemmed |
Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses |
title_sort |
ovarian cancer: new accents treatment of patients with platinum-sensitive relapses |
publisher |
ABV-press |
series |
Opuholi Ženskoj Reproduktivnoj Sistemy |
issn |
1994-4098 1999-8627 |
publishDate |
2016-11-01 |
description |
The article discussed the main treatment strategy for patients with platinum-sensitive relapsed the high-grade serous cancer of the ovaries, fallopian tube cancer and primary peritoneal cancer. The commonality of these tumors is caused by the same type of coelomic epithelium of mesodermal origin of the rudiments of Müllerian ducts, as well as similarities in the ways of carcinogenesis: the loss or inactivation of the tumor suppressor TP53, loss of function of proteins BRCA1 and BRCA2 – the controllers of DNA repair and genome integrity. Platinum drugs and PARP inhibitors have priority in treatment – “BRCA-associated” cancers. Maintenance monotherapy with the PARP inhibitor olaparib after platinum prolonged by 7 months progression-free survival. Olaparib will be to benefit patients with a BRCA mutation. Search mutations in the genes BRCA1 and BRCA2 of all high-grade ovarian cancer patients, allow to allocate patients with relapses requiring therapy resumed platinum drugs and continued the PARP inhibitor olaparib. In these cases, Lynparza (olaparib) 400 mg twice daily, as maintenance treatment in patients with platinum-sensitive relapse who had received two or more platinum-based regimens and who had a partial or complete response to their most recent platinum-based regimen and with BRCA-mutation have the greatest likelihood of benefiting from olaparib maintenance treatment. |
topic |
high grade serous ovarian cancer chemotherapy platinum-sensitive relapse brca-associated ovarian cancer ovarian cancer genetics hereditary ovarian cancer olaparib parp inhibitors |
url |
https://ojrs.abvpress.ru/ojrs/article/view/508 |
work_keys_str_mv |
AT agkedrova ovariancancernewaccentstreatmentofpatientswithplatinumsensitiverelapses AT agnikitin ovariancancernewaccentstreatmentofpatientswithplatinumsensitiverelapses AT vvkosyy ovariancancernewaccentstreatmentofpatientswithplatinumsensitiverelapses AT mvyurova ovariancancernewaccentstreatmentofpatientswithplatinumsensitiverelapses |
_version_ |
1721251603046989824 |